Trevi Therapeutics Completes Enrollment for Phase 2a RIVER Trial in Refractory Chronic Cough
Trevi Therapeutics (Nasdaq: TRVI) has completed enrollment for its Phase 2a RIVER trial, evaluating Haduvio™ (oral nalbuphine ER) for refractory chronic cough (RCC). The company expects to report topline results in Q1 2025. The trial is a randomized, double-blind, placebo-controlled study conducted in the UK and Canada, designed to assess the efficacy, safety, and tolerability of Haduvio in RCC patients.
The primary endpoint is the mean change in 24-hour cough frequency, measured by an objective cough monitor. The study includes two subgroups based on cough frequency: moderate (10-19 coughs/hour) and high (≥20 coughs/hour). Secondary endpoints include patient-reported outcome measures for cough frequency and severity. Approximately 60 adult patients were enrolled in the trial.
Trevi Therapeutics (Nasdaq: TRVI) ha completato l'arruolamento per il suo studio di Fase 2a RIVER, che valuta Haduvio™ (nalbuphina ER orale) per tosse cronica refrattaria (RCC). L'azienda prevede di riportare i risultati preliminari nel Q1 2025. Lo studio è uno studio randomizzato, in doppio cieco e controllato con placebo condotto nel Regno Unito e in Canada, progettato per valutare l'efficacia, la sicurezza e la tollerabilità di Haduvio nei pazienti con RCC.
L'endpoint principale è la variazione media nella frequenza della tosse in 24 ore, misurata tramite un monitor obiettivo della tosse. Lo studio include due sottogruppi basati sulla frequenza della tosse: moderata (10-19 colpi/ora) e alta (≥20 colpi/ora). Gli endpoint secondari includono misure dei risultati riferiti dai pazienti per la frequenza e la gravità della tosse. Sono stati arruolati circa 60 pazienti adulti nello studio.
Trevi Therapeutics (Nasdaq: TRVI) ha completado la inscripción para su ensayo de Fase 2a RIVER, que evalúa Haduvio™ (nalbufina ER oral) para tos crónica refractaria (RCC). La compañía espera informar los resultados preliminares en el Q1 de 2025. El ensayo es un estudio aleatorizado, doble ciego y controlado con placebo que se lleva a cabo en el Reino Unido y Canadá, diseñado para evaluar la eficacia, seguridad y tolerabilidad de Haduvio en pacientes con RCC.
El objetivo principal es el cambio medio en la frecuencia de tos en 24 horas, medido por un monitor de tos objetivo. El estudio incluye dos subgrupos basados en la frecuencia de tos: moderada (10-19 toses/hora) y alta (≥20 toses/hora). Los objetivos secundarios incluyen medidas de resultados autoinformados por los pacientes sobre la frecuencia y gravedad de la tos. Aproximadamente 60 adultos fueron incluidos en el ensayo.
Trevi Therapeutics (Nasdaq: TRVI)는 Haduvio™ (경구용 날부피틴 ER)를 난치성 만성 기침(RCC)에 대한 Phase 2a RIVER 시험의 등록을 완료했습니다. 회사는 2025년 1분기에 최종 결과를 보고할 것으로 예상합니다. 이 시험은 영국과 캐나다에서 시행되는 무작위 이중 맹검 위약 대조 연구로, RCC 환자에서 Haduvio의 효과, 안전성 및 내약성을 평가하기 위해 설계되었습니다.
주요 목표는 24시간 기침 빈도의 평균 변화로, 객관적인 기침 모니터를 통해 측정됩니다. 이 연구는 기침 빈도를 기준으로 두 개의 하위 그룹을 포함합니다: 중간(시간당 10-19회 기침) 및 높은(≥시간당 20회 기침). 이차 목표로는 기침 빈도 및 강도에 대한 환자 자가 보고 결과 측정이 포함됩니다. 약 60명의 성인이 시험에 등록되었습니다.
Trevi Therapeutics (Nasdaq: TRVI) a complété l'inscription pour son essai de Phase 2a RIVER, évaluant Haduvio™ (nalbuphine ER orale) pour la toux chronique réfractaire (RCC). L'entreprise s'attend à rapporter les résultats préliminaires au T1 2025. L'essai est une étude randomisée, en double aveugle et contrôlée par placebo, menée au Royaume-Uni et au Canada, conçue pour évaluer l'efficacité, la sécurité et la tolérance de Haduvio chez les patients atteints de RCC.
Le critère principal est le changement moyen de la fréquence de la toux sur 24 heures, mesuré par un moniteur objectif de la toux. L'étude comprend deux sous-groupes basés sur la fréquence de la toux : modérée (10-19 toux/heure) et élevée (≥20 toux/heure). Les critères secondaires incluent des mesures des résultats rapportés par les patients concernant la fréquence et la sévérité de la toux. Environ 60 patients adultes ont été inscrits dans l'essai.
Trevi Therapeutics (Nasdaq: TRVI) hat die Einschreibung für die Phase 2a RIVER-Studie abgeschlossen, die Haduvio™ (orale Nalbufin ER) bei therapieresistenter chronischer Husten (RCC) bewertet. Das Unternehmen erwartet, die vorläufigen Ergebnisse im 1. Quartal 2025 zu berichten. Die Studie ist eine randomisierte, doppelblinde, placebokontrollierte Studie, die im Vereinigten Königreich und Kanada durchgeführt wird und darauf abzielt, die Wirksamkeit, Sicherheit und Verträglichkeit von Haduvio bei RCC-Patienten zu bewerten.
Der primäre Endpunkt ist die durchschnittliche Veränderung der Hustenfrequenz über 24 Stunden, gemessen mit einem objektiven Hustenmonitor. Die Studie umfasst zwei Untergruppen, die auf der Hustenfrequenz basieren: moderat (10-19 Husten/Stunde) und hoch (≥20 Husten/Stunde). Die sekundären Endpunkte umfassen vom Patienten berichtete Ergebnisse bezüglich Hustenfrequenz und -schwere. Etwa 60 erwachsene Patienten wurden in die Studie aufgenommen.
- Completed enrollment for Phase 2a RIVER trial in refractory chronic cough
- Addressing a large unmet need with approximately 2-3 million adults affected by RCC in the U.S.
- Building on positive results from previous chronic cough studies in IPF
- Topline results not expected until Q1 2025, indicating a long wait for data
Insights
The completion of enrollment for Trevi Therapeutics' Phase 2a RIVER trial in refractory chronic cough (RCC) is a significant milestone. This study targets a substantial unmet medical need, with 2-3 million adults in the U.S. affected by RCC and no approved treatments available.
Key points to consider:
- The trial design is robust, featuring a randomized, double-blind, placebo-controlled, crossover study.
- The primary endpoint of mean change in 24-hour cough frequency is objectively measurable, which strengthens the potential validity of results.
- Stratification into moderate and high cough frequency subgroups may provide valuable insights into treatment efficacy across different patient populations.
- Secondary endpoints including patient-reported outcomes will offer a more comprehensive view of the treatment's impact.
While the topline results expected in Q1 2025 are still over a year away, this news indicates the study is progressing as planned. Investors should monitor for any interim updates or potential catalysts that could impact the company's valuation before the final data readout.
From a financial perspective, the completion of enrollment in the RIVER trial is a positive development for Trevi Therapeutics, but its immediate impact on the company's financials is Key considerations:
- With a market cap of
$226,486,781 , Trevi is a small-cap biopharmaceutical company, making it sensitive to clinical trial progress. - The RCC market represents a significant opportunity, potentially translating to substantial revenue if Haduvio proves effective and gains approval.
- However, investors should be cautious as the topline results are not expected until Q1 2025, which is a considerable wait in biotech terms.
- Cash runway will be crucial; investors should assess if Trevi has sufficient funds to reach this data readout without dilutive financing.
- The company's diversified approach, studying Haduvio in both RCC and IPF chronic cough, may provide some risk mitigation.
While this news is incrementally positive, it's unlikely to significantly move the stock price in the short term. Long-term investors should view this as a step towards potential value creation, contingent on positive trial results.
Topline results are expected in the first quarter of 2025
"We are happy to have completed enrollment for our Phase 2a RIVER trial for the treatment of RCC," said Jennifer Good, President and CEO of Trevi Therapeutics. "RCC impacts approximately 2-3 million adults in the
Phase 2a Trial Design: Refractory Chronic Cough Improvement Via Nal ER (RIVER)
The Phase 2a RIVER trial is a randomized, double-blind, placebo-controlled, two-treatment, two-period, crossover study designed to evaluate the efficacy, safety, tolerability and dosing of Haduvio for the treatment of RCC. The trial is being conducted at multiple sites in the
About Refractory Chronic Cough (RCC)
Refractory chronic cough has no approved therapies in the
About Trevi Therapeutics, Inc.
Trevi Therapeutics, Inc. is a clinical-stage biopharmaceutical company developing the investigational therapy Haduvio™ (oral nalbuphine extended-release (ER)) for the treatment of chronic cough in idiopathic pulmonary fibrosis (IPF) and refractory chronic cough (RCC). Haduvio acts on the cough reflex arc both centrally and peripherally as a kappa agonist and a mu antagonist (KAMA), which are opioid receptors that play a key role in controlling cough hypersensitivity. Nalbuphine is not scheduled by the
The impact of chronic cough is significant and often leads to a decline in patients' social, physical, and psychological quality of life. In IPF, chronic cough may lead to worsening disease and may be associated with a higher risk of progression, death, or need for lung transplant. There are no approved therapies for the treatment of chronic cough in IPF and current treatment options provide minimal benefit to patients. Chronic cough affects up to
Trevi intends to propose Haduvio as the trade name for oral nalbuphine ER. Its safety and efficacy have not been evaluated by any regulatory authority.
For more information, visit www.TreviTherapeutics.com and follow Trevi on X (formerly Twitter) and LinkedIn.
Forward-Looking Statements
Statements contained in this press release regarding matters that are not historical facts are "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements are subject to risks and uncertainties and actual results may differ materially from those expressed or implied by such forward-looking statements. Such statements include, but are not limited to, statements regarding Trevi's expectation of reporting topline data from Trevi's Phase 2a RIVER trial in the first quarter of 2025. Risks that contribute to the uncertain nature of the forward-looking statements include uncertainties regarding the success and timing of Trevi's product candidate development activities, including its ongoing clinical trials, uncertainties regarding Trevi's ability to execute on its strategy, as well as other risks and uncertainties set forth in the quarterly report on Form 10-Q for the quarter ended June 30, 2024 filed with the Securities and Exchange Commission and in subsequent filings with the Securities and Exchange Commission. All forward-looking statements contained in this press release speak only as of the date on which they were made. Trevi undertakes no obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they were made.
Investor Contact
Katie Barrett
Trevi Therapeutics, Inc.
203-304-2499
k.barrett@trevitherapeutics.com
Media Contact
Rosalia Scampoli
914-815-1465
rscampoli@marketcompr.com
View original content to download multimedia:https://www.prnewswire.com/news-releases/trevi-therapeutics-completes-enrollment-for-phase-2a-river-trial-in-refractory-chronic-cough-302281016.html
SOURCE Trevi Therapeutics, Inc.
FAQ
What is the primary endpoint of Trevi Therapeutics' RIVER trial for TRVI?
When does Trevi Therapeutics (TRVI) expect to report topline results for the RIVER trial?
How many patients were enrolled in Trevi Therapeutics' Phase 2a RIVER trial for TRVI?